# US 2006/0078545 A1 · Neural progenitor cell populations

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0078545 A1
- Document ID: US20060078545A1
- Status: Published application
- Kind: A1
- Application number: 11/281,040
- Filed: 2005-11-16
- Published: 2006-04-13
- Earliest claimed: 2000-05-17
- Assignees: Geron Corporation
- Inventors: Melissa Carpenter
- Web page: https://patentgrep.com/patent/US20060078545A1

## CPC

- C12N 5/0618: {Cells of the nervous system}
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/08: Vasodilators for multiple indications
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 5/0623: {Stem cells}
- C12Q 1/6881: for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
- A61K 35/12: Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells (vaccines or medicinal preparations containing antigens or antibodies A61K39/00)
- C12N 2501/01: Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
- C12N 2501/105: Insulin-like growth factors [IGF]
- C12N 2501/11: Epidermal growth factor [EGF]
- C12N 2501/115: Basic fibroblast growth factor (bFGF, FGF-2)
- C12N 2501/119: Other fibroblast growth factors, e.g. FGF-4, FGF-8, FGF-10
- C12N 2501/13: Nerve growth factor [NGF]; Brain-derived neurotrophic factor [BDNF]; Cilliary neurotrophic factor [CNTF]; Glial-derived neurotrophic factor [GDNF]; Neurotrophins [NT]; Neuregulins
- C12N 2501/135: Platelet-derived growth factor [PDGF]
- C12N 2503/02: Drug screening
- C12N 2506/02: from embryonic cells
- C12N 2510/00: Genetically modified cells
- C12Q 2600/158: Expression markers
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

This invention provides populations of neural progenitor cells, differentiated neurons, glial cells, and astrocytes. The populations are obtained by culturing stem cell populations (such as embryonic stem cells) in a cocktail of growth conditions that initiates differentiation, and establishes the neural progenitor population. The progenitors can be further differentiated in culture into a variety of different neural phenotypes, including dopaminergic neurons. The differentiated cell populations or the neural progenitors can be generated in large quantities for use in drug screening and the treatment of neurological disorders.

## Claims

### Claim 1

A cell population that proliferates in an in vitro culture, obtained by differentiating primate pluripotent stem (pPS) cells, wherein at least ˜30% of the cells in the population are committed to form neuronal cells, glial cells, or both.

### Claim 2

A cell population that proliferates in an in vitro culture, obtained by differentiating primate pluripotent stem (pPS) cells, comprising at least ˜60% neural progenitor cells, wherein at least 10% of the cells can differentiate into neuronal cells, and at least 10% of the cells can differentiate into glial cells.

### Claim 3

A cell population that proliferates in an in vitro culture, obtained by differentiating primate pluripotent stem (pPS) cells, comprising at least ˜60% neural progenitor cells, wherein at least 10% of the cells express A2B5, and at least 10% of the cells express NCAM.

### Claim 4 (depends on 1)

The cell population of claim 1, wherein the pPS cells are human embryonic stem (hES) cells.

### Claim 5 (depends on 1)

The cell population of claim 1, obtained by differentiating pPS cells in a medium containing at least two ligands that bind growth factor receptors, selected from the group consisting of EGF, bFGF, PDGF, IGF-1, and antibodies to receptors for these ligands.

### Claim 6 (depends on 1)

The cell population of claim 1, obtained by differentiating pPS cells in a medium containing growth factors, sorting the differentiated cells for expression of NCAM or A2B5, and then collecting the sorted cells.

### Claim 7 (depends on 1)

The cell population of claim 1, which can be induced to produce a population of cells of which at least 30% of the cells have morphological features of mature neurons and are NCAM positive.

### Claim 8 (depends on 7)

The cell population of claim 7, wherein the cells having morphological features of mature neurons have at least three of the following characteristics:
a) at least 60% of the cells show calcium flux when administered acetylcholine;
b) at least 60% of the cells show calcium flux when administered GABA;
c) at least 10% of the cells show calcium flux when administered norepinephrine;
d) at least 60% of the cells show calcium flux when subjected to an external potassium concentration of 50 mM; or
e) at least 25% of the cells demonstrate action potentials when subject to stimulation in a whole-cell patch clamp apparatus.

### Claim 9 (depends on 1)

The cell population of claim 1, which can be induced to produce a population of cells in which at least 1% of the cells stain positively for tyrosine hydroxylase.

### Claim 10 (depends on 1)

The cell population of claim 1, comprising cells genetically altered to express telomerase reverse transcriptase.

### Claim 11 (depends on 1)

A cell population comprising mature neurons, astrocytes, oligodendrocytes, or any combination thereof, obtained by further differentiating the cell population according to claim 1.

### Claim 12 (depends on 11)

The cell population of claim 11, comprising a subpopulation of at least 30% of the cells that have the morphological characteristics of neurons and are NCAM positive, wherein the subpopulation has the following properties:
a) at least 60% show calcium flux when administered acetylcholine;
b) at least 60% show calcium flux when administered GABA;
c) at least 10% show calcium flux when administered norepinephrine;
d) at least 60% show calcium flux when subjected to an external potassium concentration of 50 mM; or
e) at least 25% demonstrate action potentials when subject to stimulation in a whole-cell patch clamp apparatus.

### Claim 13 (depends on 11)

The cell population of claim 11, in which at least 1% of the cells stain positively for tyrosine hydroxylase.

### Claim 14 (depends on 1, 11)

The cell population of claim 11, obtained by culturing the cell population of claim 1 in a medium containing an activator of cAMP, a neurotrophic factor, or a combination thereof.

### Claim 15 (depends on 1)

An isolated neural precursor cell, obtained by providing the cell population of claim 1, and selecting therefrom a cell having characteristics of a neural precursor cell.

### Claim 16 (depends on 11)

An isolated mature neuron, astrocyte, or oligodendrocyte, obtained by providing the cell population of claim 11, and selecting therefrom a cell having characteristics of a neuron, astrocyte, or oligodendrocyte, respectively.

### Claim 17 (depends on 16)

The isolated mature neuron of claim 16, which is a dopaminergic neuron.

### Claim 18 (depends on 1, 16)

The isolated mature neuron of claim 16, obtained by culturing the cell of claim 1 in a medium containing an activator of cAMP, a neurotrophic factor (such as nerve growth factor, neurotrophin 3, or brain-derived neurotrophic factor), or a combination thereof.

### Claim 19

A cell population comprising at least ˜60% neural progenitor cells and/or mature neurons that have the same genome as an established human embryonic stem (hES) cell line.

### Claim 20 (depends on 18)

The cell population of claim 18, wherein the neural progenitor cells and/or mature neurons express NCAM, A2B5, MAP-2, or Nestin.

### Claim 21

A method for obtaining neural precursor cells capable of producing a cell population comprising at least 1% tyrosine hydroxylase positive cells, comprising differentiating human embryonic stem cells.

### Claim 22 (depends on 21)

The method of claim 21, wherein the differentiating comprises culturing in a medium containing at least two ligands that bind growth factor receptors, selected from the group consisting of EGF, bFGF, PDGF, IGF-1, and antibodies to receptors for these ligands.

### Claim 23

A method for obtaining a cell population comprising at least 1% tyrosine hydroxylase positive cells, comprising differentiating human embryonic stem cells.

### Claim 24 (depends on 19, 21)

The method of claim 21, comprising obtaining neural precursor cells according to claim 19, and then culturing the cells obtained thereby in a medium containing an activator of cAMP, a neurotrophic factor (such as nerve growth factor, neurotrophin 3, or brain-derived neurotrophic factor), or a combination thereof.

### Claim 25 (depends on 21)

The method of claim 21, further comprising genetically altering the cells to express telomerase reverse transcriptase before or after differentiating.

### Claim 26 (depends on 1)

A method of screening a compound for neural cell toxicity or modulation, comprising combining the compound with a cell population according to claim 1; determining any phenotypic or metabolic changes in the cell that result from contact with the compound; and correlating the change with neural cell toxicity or modulation.

### Claim 27 (depends on 11)

A method of screening a compound for neural cell toxicity or modulation, comprising combining the compound with a cell population according to claim 11; determining any phenotypic or metabolic changes in the cell that result from contact with the compound; and correlating the change with neural cell toxicity or modulation.

### Claim 28 (depends on 1)

A method for obtaining a polynucleotide comprising a nucleotide sequence contained in an mRNA more highly expressed in neural progenitor cells, the method comprising:
a) determining the level of expression of a plurality of mRNAs in one or more cells in the cell population of claim 1, in comparison to the level of expression of the same mRNAs in more mature neural cells;
b) identifying an mRNA expressed at a higher level in the cell(s) from the cell population, relative to that in the more mature cells; and
c) preparing a polynucleotide comprising a nucleotide sequence of at least 30 consecutive nucleotides contained in the mRNA selected in step b).

### Claim 29 (depends on 1)

A method of reconstituting or supplementing central nervous system (CNS) function in an individual, comprising administering to the individual a cell population according to claim 1.

### Claim 30 (depends on 11)

A method of reconstituting or supplementing CNS function in an individual, comprising administering to the individual a cell population according to claim 11.
